Primary-source record

Decision-gradeComplete response letter

Summit Receives FDA CRL for Ivonescimab BLA in EGFR-Mutated NSCLC

FDA issued a Complete Response Letter for the BLA of ivonescimab plus chemotherapy in EGFR-mutated NSCLC after prior TKI. The CRL states that substantial evidence of effectiveness is not established without statistically significant OS improvement, as PFS benefit alone does not support a positive benefit-risk profile. The HARMONi Phase 3 trial met its PFS primary endpoint but showed only a positive OS trend without statistical significance.

Key facts

Filed
Nov 15, 2026, 12:00 PM
Event
Complete response letter
Direction
Negative
Source
SEC 8-K
Confidence
Sourced
Calendar
FDA decision (PDUFA) · Nov 14, 2026 · Complete response letter
PFS HR
0.52
OS trend
positive but not statistically significant

Source excerpt

Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application Complete Response Letter Received from FDA for BLA Application Based on HARMONi Study Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. Ivonescimab is a novel PD-1 x VEGF bispecific antibody. “As a cancer survivor, I understand firsthand how important it is for patients to have access to multiple treatment options, particularly when they are facing diseases with significant unmet medical needs,” emphasized Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics. “Behind every diagnosis is a person, a family, and a community hoping for more time, more possibilities, and a better future. I know that hope is not simply an emotion; it is the possibility that another treatment, another scientific breakthrough, or another therapeutic option may make a meaningful difference i

SEC 8-K

More on this asset

Nov 5, 2026
03:24 PM
SMMTSummit Therapeutics

ivonescimab · NCT07228832 registry update

Trial registry changeClinicalTrials.gov1 update
Oct 28, 2026
03:22 PM
SMMTSummit Therapeutics

ivonescimab · NCT07158489 registry update

Trial registry changeClinicalTrials.gov
Oct 22, 2026
10:00 AM
SMMTSummit Therapeutics

Summit Therapeutics to Present Ivonescimab Data Across 10 Abstracts at ESMO 2026

Conference presentationCompany press release
Oct 19, 2026
11:00 AM
SMMTSummit Therapeutics

Summit Therapeutics opens Phase II SMT112-216 trial of ivonescimab regimens in 1L advanced ccRCC

Trial registry changeCompany press release1 update
Oct 6, 2026
03:21 PM
SMMTSummit Therapeutics

ivonescimab · NCT07228832 registry update

Trial registry changeClinicalTrials.gov
Summit Receives FDA CRL for Ivonescimab BLA in EGFR-Mutated NSCLC | SimianX AI